HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Lubrizol debuts paraben alternative

This article was originally published in The Rose Sheet

Executive Summary

With the negative perception of paraben and formaldehyde preservatives in the marketplace, and shift to food-grade preservatives like sodium benzoate, Lubrizol Corporation releases Carbopol Aqua SF-2 polymer. Product is a "rheology modifier" that "delivers high clarity and superior suspension in the 4 to 6 pH range," says the Cleveland, Ohio-based company in a Sept. 13 release. Product will accommodate natural preservatives that require a pH level near 5 without sacrificing formulation clarity or flow properties, according to Lubrizol. "Now formulators can display colorful beads, sparkling pearls and exfoliating scrubs while also achieving claims of 'paraben-free,' 'formaldehyde-free,' 'preservative-free' and even 'skin neutral pH,'" firm explains. Potential uses for the polymer include clear bath gels, body scrubs with suspended microcapsules, facial scrubs with exfoliating beads, anti-acne facial cleansers with salicylic acid, pearlescent shampoos and soap-based cleansers

You may also be interested in...

Top FDA Officials: Agency Actively Cracking Down On Medical Products With Sham COVID-19 Claims

US FDA commissioner Stephen Hahn and ORA associate commissioner for regulatory affairs Judith McMeekin said in a joint 24 February statement that the agency continues to aggressively monitor the market for any firms selling products with fraudulent COVID-19 prevention and treatment claims. The officials also explained that the FDA has the authority to ask for records from drug manufacturers in lieu of conducting facility inspections, but they didn’t say whether the agency would – or even could – ask the same of device makers. The FDA had announced on 14 February that it paused all inspections of Chinese manufacturing facilities in the near-term.

Execs On The Move: Conformis And EyeKor Make Major Management Changes

Knee implant manufacturer Conformis Inc. brings aboard new chief financial officer/treasurer and operations SVP; imaging and data management software company EyeKor promoted its president/CTO to CEO; and more.

Expanded Lung Cancer Claim For Lilly’s Cyramza Faces US FDA Scrutiny

Oncologic Drugs Advisory Committee will consider whether a statistically significant benefit on progression-free survival, but no survival advantage, is enough to secure a first-line lung cancer indication for ramucirumab.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts